Indivior (NASDAQ:INDV) Shares Gap Up - What's Next?

Shares of Indivior PLC (NASDAQ:INDV - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $12.18, but opened at $12.54. Indivior shares last traded at $12.56, with a volume of 21,575 shares trading hands.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Piper Sandler reissued an "overweight" rating and issued a $16.00 target price (up from $15.00) on shares of Indivior in a report on Friday, October 25th. Craig Hallum dropped their price target on shares of Indivior from $20.00 to $16.00 and set a "buy" rating on the stock in a research note on Friday, October 11th.

Indivior Trading Up 2.1 %

The stock has a market cap of $1.71 billion, a PE ratio of -310.67 and a beta of 0.75. The stock's fifty day moving average price is $10.69 and its 200 day moving average price is $11.45. The company has a quick ratio of 0.65, a current ratio of 0.83 and a debt-to-equity ratio of 23.50.

Indivior (NASDAQ:INDV - Get Free Report) last issued its earnings results on Thursday, October 24th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.39 by $0.15. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. The business had revenue of $307.00 million for the quarter, compared to the consensus estimate of $302.25 million. On average, sell-side analysts forecast that Indivior PLC will post 1.68 EPS for the current year.

Hedge Funds Weigh In On Indivior

Hedge funds have recently bought and sold shares of the business. Iron Triangle Partners LP bought a new stake in shares of Indivior in the third quarter worth approximately $8,243,000. Krensavage Asset Management LLC purchased a new stake in Indivior in the third quarter worth approximately $6,843,000. Millennium Management LLC grew its position in Indivior by 48.1% in the 2nd quarter. Millennium Management LLC now owns 493,313 shares of the company's stock worth $7,952,000 after purchasing an additional 160,282 shares during the period. Stonepine Capital Management LLC purchased a new stake in Indivior during the third quarter valued at $2,632,000. Finally, Clark Estates Inc. NY purchased a new stake in shares of Indivior during the 3rd quarter valued at about $2,477,000. Hedge funds and other institutional investors own 60.33% of the company's stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.